09/925,883

* * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:38:46 ON 07 MAR 2005

=> file reg

=>
Uploading C:\Program Files\Stnexp\Queries\09925883.str





chain nodes :
11 12 13 15 16 19 27 28 29
ring nodes :
1 2 3 4 5 6 7 8 9 10 20 21 22 23 24 25
chain bonds :
2-29 3-28 4-27 5-19 9-11 11-12 11-13 15-16 19-20
ring bonds :
1-2 1-6 1-10 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10 20-21 20-25 21-22 22-23
23-24 24-25
exact/norm bonds :
4-27 5-19 9-11 11-12 11-13 15-16 19-20
exact bonds :
2-29 3-28
normalized bonds :
1-2 1-6 1-10 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10 20-21 20-25 21-22 22-23
23-24 24-25
isolated ring systems :
containing 1 :

G1:CH2,SO2,S,[*1-*2]

G2:C,O,CN,X

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 13:CLASS 15:CLASS 16:CLASS 19:CLASS 20:Atom 21:Atom
22:Atom 23:Atom 24:Atom 25:Atom 27:CLASS 28:CLASS 29:CLASS

```
L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l1 full

L3            39 SEA SSS FUL L1

=> file ca

=> s l3
L4            1 L3

=> d ibib abs fhitstr hitrn
```

L4 ANSWER 1 OF 1 CA COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 136:183715 CA
TITLE: Preparation of quinoline derivatives as antiinflammatory agents
INVENTOR(S): Broka, Chris Allen; Kim, Woongki; McLaren, Kevin Lee; Smith, David Bernard
PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.
SOURCE: PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002012192	A1	20020214	WO 2001-EP8880	20010801
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2418832	AA	20020214	CA 2001-2418832	20010801
AU 2001077560	A5	20020218	AU 2001-77560	20010801
EP 1313707	A1	20030528	EP 2001-955382	20010801
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001013175	A	20040217	BR 2001-13175	20010801
JP 2004505951	T2	20040226	JP 2002-518170	20010801
US 2002082276	A1	20020627	US 2001-925883	20010807
ZA 2003000847	A	20040430	ZA 2003-847	20030130
PRIORITY APPLN. INFO.:			US 2000-224196P	P 20000809
			WO 2001-EP8880	W 20010801

OTHER SOURCE(S): MARPAT 136:183715
GI


I



AB The title compds. I [A = S, etc.; Ar = (un)substituted phenyl; R1 = H, alkoxy, etc.; R2 = H, alkyl, etc.; R3 = SO2R12, etc.; R12 = alkyl, etc.] are prepared I are useful as inhibitors of COX-II and, therefore, may be used for the treatment of a disease treatable by administration of a selective COX-II inhibitor, such as an inflammatory disease, autoimmune disease. Processes for preparing I are claimed. 5-(2,4-Difluorophenylsulfanyl)-2-methanesulfonyl-6-methoxyquinoline in vitro showed IC50 values of >40 μM and <0.2 μM against COX-I and COX-II, resp. Formulations are given.

IT **398456-42-3P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of quinoline derivs. as antiinflammatory agents)

RN 398456-42-3 CA
CN 6-Quinolinol, 5-[(4-fluorophenyl)thio]-2-(methylsulfonyl)- (9CI) (CA INDEX NAME)



IT **398456-42-3P 398456-44-5P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of quinoline derivs. as antiinflammatory agents)

IT **398456-13-0P 398456-14-9P 398456-15-0P**
398456-16-1P 398456-17-2P 398456-18-3P
398456-19-4P 398456-20-7P 398456-21-8P
398456-22-9P 398456-23-0P 398456-24-1P
398456-25-2P 398456-26-3P 398456-27-4P
398456-28-5P 398456-29-6P 398456-30-9P
398456-31-0P 398456-32-1P 398456-33-2P
398456-34-3P 398456-35-4P 398456-36-5P
398456-37-6P 398456-38-7P 398456-39-8P
398456-40-1P 398456-41-2P 398456-43-4P
398456-45-6P 398456-46-7P 398456-47-8P
398456-48-9P 398456-60-5P 398456-61-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinoline derivs. as antiinflammatory agents)

IT **398456-72-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of quinoline derivs. as antiinflammatory agents)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 1 OF 1 CA COPYRIGHT 2005 ACS on STN (Continued)

L4 ANSWER 1 OF 1 CA COPYRIGHT 2005 ACS on STN (Continued)

09/925,883

=> file marpat

=> s l1 full

L5 21 SEA SSS FUL L1

=> d ibib abs fqhit 1-21

L5 ANSWER 1 OF 21 MARPAT COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 141:350049 MARPAT
TITLE: Preparation of (hetero)arylurea derivatives as deformylase inhibitors with antibacterial activity
INVENTOR(S): Lee, Bong-Jin; Lee, Seung-Kyu; Choi, Kwang-Hyun; Lee, Sang-Jae
PATENT ASSIGNEE(S): Promeditech Inc., S. Korea
SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004087643	A1	20041014	WO 2004-KR502	20040311

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: KR 2003-20486 20030401
AB The title compds. HONHCOCH2N(R1)COCH(R2)NHCONHX (I) [R1 = C1 to C6 alkyl, or C1 to C2 alkyl substituted with C3 to C6 cycloalkyl group; R2 = C1 to C6 alkyl; X = Ph, etc.] are prepared The title deformylase inhibitors effectively act against a broad spectrum of bacteria, including bacteria with resistance to existing antibacterial agents. A process for preparing I is disclosed. Thus, 1-{(S)-1-(N-((hydroxycarbamoyl)methyl)-N-butylcarbamoyl)-2,2-dimethylpropyl)-3-(3-chlorophenyl)urea (II) was prepared in a multistep process starting from glycine Et ester hydrochloride and 1-bromobutane. II in vitro showed IC50 of 28 nM against deformylase.

MSTR 1

G5—G3

G3 = quinolinyl (SO (1-3) G4)
G4 = CN / SO2Me / COPh
MPL: claim 1
NTE: also incorporates claims 5, 6, and 7
NTE: or pharmaceutically acceptable salts

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 21 MARPAT COPYRIGHT 2005 ACS on STN (Continued)



G23 = N
G24 = alkylcarbonyl<(1-4)> / CH2Ph
G29 = S(O)
G30 = CH2Ph
G31 = 79-6 74-75 73-72

MPL: claim 1
NTE: substitution is restricted
NTE: or pharmaceutically acceptable salts
NTE: also incorporates claims 8,14 and 20
NTE: additional ring formation also claimed

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 21 MARPAT COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 141:106488 MARPAT
TITLE: Preparation of pyrazolo[3,4-d]pyrimidine derivatives for treatment of H.pylori infection
INVENTOR(S): Basarab, Gregory; Eyermann, Joseph; Gowravaram, Madhusudhan; Green, Oluyinka; Macpherson, Lawrence; Morningstar, Marshall; Nguyen, Thanh
PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.
SOURCE: PCT Int. Appl., 129 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004056831	A1	20040708	WO 2003-SE2033	20031219

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: SE 2002-3825 20021220
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. I-IV [wherein X = S, O, or NR20, with exclusions; W = S, O, or NR20, with an exclusion; R1 = H, (un)substituted alkyl, alkenyl, etc.; R2 = H, (un)substituted alkyl, alkenyl, etc.; R3 = (hetero)cyclyl; R4 = (hetero)cyclyl; R20 = H, CN, (un)substituted alkyl, etc.] or pharmaceutically acceptable salts thereof are prepared for the treatment or prophylaxis of H. pylori infection. For example, the compound V was prepared in a multi-step synthesis. These compds. showed IC50 of <400 μM against glutamate racemase.

MSTR 1



G8 = 102

L5 ANSWER 3 OF 21 MARPAT COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 140:94045 MARPAT
TITLE: Preparation of hypoglycemic imidazoline compounds
INVENTOR(S): Takeuchi, Kumiko; Jirousek, Michael Robert; Paal, Michael; Ruhter, Gerd; Schotten, Theo
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 106 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004009976	A1	20040115	US 2002-135963	20020430

PRIORITY APPLN. INFO.: US 2002-135963 20020430
GI



I

AB The title compds. I [X = O, S, NR5 with R5 = H, alkyl, protecting group; R1, R1', R2, R3 = H, alkyl; R1 and R2 form a bond and R1' and R3 are H, alkyl; or R1 and R2 form a carbocyclic ring; R4 = (un)substituted indolyl, naphthyl, quinolinyl, etc.; n = 0-2], useful for treating diabetes, diabetic complications, metabolic disorders or related diseases where impaired glucose disposal is present, were prepared and formulated. E.g., preparation of 5-chloro-2-methyl-3-(4,5-dihydro-1H-imidazol-2-yl)-1H-indole is described.

MSTR 1C

G9 = 178



L5 ANSWER 3 OF 21 MARPAT COPYRIGHT 2005 ACS on STN (Continued)
G14 = alkylene<(1-8)>
G15 = Ph (SO)
G28 = alkoxycarbonyl<(1-8)>
G30 = S(O)
G31 = alkyl<(1-10)>
MPL: claim 1
NTE: substitution is restricted

L5 ANSWER 4 OF 21 MARPAT COPYRIGHT 2005 ACS on STN (Continued)
G13 = quinolinyl (SO (1-2) G14)
G14 = CN / alkylsulfinyl<(1-6)> / COPh
MPL: claim 1
NTE: or pharmaceutically acceptable salts

L5 ANSWER 4 OF 21 MARPAT COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 139:364692 MARPAT
TITLE: Preparation of substituted phenyl compounds for the treatment of non-insulin dependent diabetes mellitus
INVENTOR(S): Sabatucci, Joseph P.; Caufield, Craig E.; Greenfield, Alexander A.; Morris, Koi M.; Morrison, Eamonn P.
PATENT ASSIGNEE(S): Wyeth, John, and Brother Ltd., USA
SOURCE: U.S. Pat. Appl. Publ., 21 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003203941	A1	20031030	US 2003-408912	20030408
PRIORITY APPLN. INFO.:			US 2002-371540P	20020410

GI



I



II

AB The title compds. [I; Y = O, S, N, C:C, C:N; R1 = SO2CF3, SO2Ar, SO2Me, CONH2, etc.; Ar = (un)substituted Ph, naphthyl, quinolyl; R2, R3 = H, halo, OH, etc.; R4 = H, halo, alkoxy; A = a bond, divalent group such as (un)substituted imidazole, thiazole, oxazole, etc.; B = CH2, CH2CHR5, CHR5CH2, CHR9R10; R5, R9, R10 = alkyl, F, H] that are useful in treating metabolic disorders mediated by insulin resistance or hyperglycemia, were prepared E.g., a 3-step synthesis of II (starting from 3-(2-hydroxyethyl)phenylamine and 4-bromobenzyl chloride) which showed 34% reduction [day 3 (6 h) p.o.] in plasma glucose at 5 mg/kg, was given. Pharmaceutical composition comprising the compound I is claimed.

MSTR 1



L5 ANSWER 5 OF 21 MARPAT COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 139:265380 MARPAT
TITLE: Hair dye compositions containing quinolinium salts
INVENTOR(S): Sauter, Guido; Braun, Hans-Juergen; Duc-Reichlin, Nadia
PATENT ASSIGNEE(S): Wella Aktiengesellschaft, Germany
SOURCE: Eur. Pat. Appl., 14 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1346719	A1	20030924	EP 2002-25423	20021115
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
DE 10211413	A1	20030925	DE 2002-10211413	20020315
US 2003177592	A1	20030925	US 2003-361380	20030210
BR 2003000496	A	20040810	BR 2003-496	20030313
PRIORITY APPLN. INFO.:			DE 2002-10211413	20020315

AB The invention concerns hair dyes that are prepared from two components; component A1 contains a quinolinium derivative; component A2 includes a nucleophile compound Other direct dyes can be added; solns., emulsions, creams, foams, gels can be formulated. Thus component A1 contained (g): 4-chloro-1-ethylquinolinium tetrafluoroborate 0.70 decyl glycoside 4.0; EDTA disodium salt 0.2; ethanol 5.0; water to 100. Component A2 included: 1,4-diaminobenzene 0.27; decyl glycoside 4.0; EDTA disodium salt 0.2; ethanol 5.0; 25% ammonia soln. 6.0; water to 100.

MSTR 1



G2 = CH2Ph / 37



MPL: claim 1

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 21 MARPAT COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 138:294931 MARPAT
TITLE: Positive working printing plate material for infrared laser exposure
INVENTOR(S): Miyake, Hideo; Oda, Akio; Mitsumoto, Tomoyoshi
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 25 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003098657	A2	20030404	JP 2001-289220	20010921

PRIORITY APPLN. INFO.: JP 2001-289220 20010921
GI



I II

AB The material has an image forming layer containing a water-insol. and alkali-soluble resin (A), an IR absorbing dye (B), and ≥1 of I and II [R1-9 = H or each (substituted) alkyl, alkenyl, aryl, allyl, or halo], in which solubility to an alkaline aqueous solution is increased by IR laser exposure. It may have ≥2 image forming layers containing the resin A, in which ≥1 of the layers contains ≥1 of I and II and ≥1 of the layers contains the dye B. It shows improved image-forming layer strength and wear prevention.

MSTR 1

G1 = CH2CH=CH2 (SO) / S(O)Me / COPh
G2 = 9

L5 ANSWER 6 OF 21 MARPAT COPYRIGHT 2005 ACS on STN (Continued)



MPL: claim 1
NTE: additional ring formation also claimed

L5 ANSWER 7 OF 21 MARPAT COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 138:271682 MARPAT
TITLE: Preparation of cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme for treatment of inflammatory disorders
INVENTOR(S): Ott, Gregory; Chen, Xiao-Tao; Duan, Jingwu; Lu, Zhonghui
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 344 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003024899	A2	20030327	WO 2002-US29685	20020916
WO 2003024899	A3	20031127		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003139388	A1	20030724	US 2002-244626	20020916
US 6740649	B2	20040525		
EP 1427408	A2	20040616	EP 2002-775865	20020916
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				

PRIORITY APPLN. INFO.: US 2001-322630P 20010917
WO 2002-US29685 20020916
GI



I



II

L5 ANSWER 7 OF 21 MARPAT COPYRIGHT 2005 ACS on STN (Continued)

AB Title compds. I [wherein ring B = (un)substituted 4-7 membered (hetero)cyclic ring containing 0-2 O, N, NR1, or SOp atoms and 0-3 carbonyl groups; R1 and R2 = independently Q, alk(en/yn)ylene-Q, or (un)substituted alkylene-Q interrupted by O, NRa, CO, CO2, CONRa, NRaCO, NRaCO2, NRaCONRa, SOp, NRaSO2, or SO2NRa; or R1 = (un)substituted alkylene-Q interrupted by OCO, OCO2, or OCONRa; Q = H or (un)substituted (hetero)cyclyl; R3 = Q1, Cl, F, alk(en/yn)ylene-Q1, or (un)substituted alkylene-Q1 interrupted by O, NR1, NRaCO, CONRa, CO, CO2, SOp, or SO2NRa; Q1 = H or (un)substituted Ph, naphthyl, or heterocyclyl; Za = (un)substituted benzimidazolyl, indolyl, imidazopyridinyl, pyrazolylpyridinyl, benzofuranyl, benzothiazinyl, quinolinyl, etc.; Ra = independently H, alkyl, Ph, or benzyl; p = 0-2; or stereoisomers or pharmaceutically acceptable salts thereof] were prepared as inhibitors of matrix metalloproteinases (MMP), TNF-a converting enzyme (TACE), aggrecanase, or a combination thereof. For example, reaction of benzyl Me maleate with paraformaldehyde and glycine gave benzyl Me (cis)-3,4-pyrrolidinedicarboxlyate (100%). BOC-protection (64%), debenzylation (96%), resolution of the (3S,4S)-isomer with (S)-α-methylbenzylamine, conversion to the carbamate with DPPA and PhCH2OH (76%), and Pd catalyzed hydrogenation (100%) provided Me (3S,4S)-4-amino-1-(tert-butoxycarbonyl)-3-pyrrolidinecarboxylate. Coupling of the amine with 4-[(2-methylthio-1H-benzimidazol-1-yl)methyl]benzoic acid (preparation given) afforded the amide (99%), which was treated with NH2OH•HCl/MeONa to give the hydroxamic acid (3S,4S)-II (33%). A number of the compds. of the invention inhibited MMP-1, 2, 3, 7, 8, 9, 10, 12, 13, 14, 15, and/or 16 with Ki values of ≤ 10 μM. Thus, I are useful for the treatment of a wide variety of inflammatory disorders (no data).

MSTR 1



G3 = 16



G5 = 80-13 78-44 81-17 82-20

G14 = Ph / CH2Ph
G15 = S(O) / SO2
G29 = CN

L5 ANSWER 7 OF 21 MARPAT COPYRIGHT 2005 ACS on STN (Continued)
MPL: claim 1
NTE: or pharmaceutically acceptable salts
NTE: substitution is restricted
NTE: additional ring formation also claimed
STE: or stereoisomers

L5 ANSWER 8 OF 21 MARPAT COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 138:78134 MARPAT
TITLE: Direct hair dyes composed of 1-benzopyrane-derivatives and an electrophilic substance
INVENTOR(S): Sauter, Guido; Braun, Hans-Juergen; Brouillard, Raymond; Fougerousse, Andre; Roehri-Stoeckel, Christine
PATENT ASSIGNEE(S): Wella Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003000214	A1	20030103	WO 2002-EP1194	20020206
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10130144	A1	20030102	DE 2001-10130144	20010622
BR 2002005662	A	20030715	BR 2002-5662	20020206
EP 1404289	A1	20040407	EP 2002-714147	20020206
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004521144	T2	20040715	JP 2003-506861	20020206
US 2003196281	A1	20031023	US 2003-380896	20030320
PRIORITY APPLN. INFO.:			DE 2001-10130144	20010622
			WO 2002-EP1194	20020206

AB The invention concerns a two component hair dye where the components are mixed in the presence of acids or bases if required to form a direct dye that can be removed with sulfite-containing reducing agents if required. The first component includes 1-benzopyrane-derivs.; the second component contains an electrophilic substance that is selected from the group of carbonyls, imines and 1-alkyl-quinoline derivs. Thus a first components was composed of (g): 7-hydroxy-4-methyl-2-phenyl-1-benzylpyrylium chloride 3.14; cetylstearyl alc. 12.0; Brij 78 P 2.8; ethanol 24.8; water to 100. The second component was a mixture of (g): 4-hydroxy-3-methoxy-benzaldehyde 1.75; cetylstearyl alc. 12.0; Brij 78 P 2.8; ethanol 24.8; water to 100.

MSTR 2

G1—G3 G10

G1 = 10

L5 ANSWER 8 OF 21 MARPAT COPYRIGHT 2005 ACS on STN (Continued)



G3 = CH2Ph / 57

MPL: claim 1

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 21 MARPAT COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 137:190369 MARPAT
TITLE: Hair dyes containing cationic quinolinium direct dyes
PATENT ASSIGNEE(S): Wella A.-G., Germany
SOURCE: Ger. Gebrauchsmusterschrift, 25 pp.
CODEN: GGXXFR
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 20204129	U1	20020829	DE 2002-20204129	20020315
PRIORITY APPLN. INFO.:			DE 2002-20204129	20020315

AB The invention concerns hair dye compns. that contain cationic direct dyes from the group of quinolinium salts. The compns. further contain other direct dyes, e.g. azo dyes, quinone dyes, and triphenylmethanes. Oxidative dyes, oxidation agent, synthetic polymers or modified natural polymers can be included. Thus 4-[(4-aminophenyl)amino]-1-ethylquinolinium-tetrafluoroborate was synthesized and used at an amount of 0.01 g in a dye that also included 10.00 g ethanol and 10.00 g water. The dye mixture was diluted with 10% citric acid or 10% ammonia solution for testing the color effects.

MSTR 1



G10

G2 = CH2Ph / 58

MPL: claim 1
NTE: additional ring formation also claimed

L5 ANSWER 10 OF 21 MARPAT COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 136:183715 MARPAT
TITLE: Preparation of quinoline derivatives as antiinflammatory agents
INVENTOR(S): Broka, Chris Allen; Kim, Woongki; McLaren, Kevin Lee; Smith, David Bernard
PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.
SOURCE: PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002012192	A1	20020214	WO 2001-EP8880	20010801
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2418832	AA	20020214	CA 2001-2418832	20010801
AU 2001077560	A5	20020218	AU 2001-77560	20010801
EP 1313707	A1	20030528	EP 2001-955382	20010801
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001013175	A	20040217	BR 2001-13175	20010801
JP 2004505951	T2	20040226	JP 2002-518170	20010801
US 2002082276	A1	20020627	US 2001-925883	20010807
ZA 2003000847	A	20040430	ZA 2003-847	20030130
PRIORITY APPLN. INFO.:			US 2000-224196P	20000809
			WO 2001-EP8880	20010801

GI



I

AB The title compds. I [A = S, etc.; Ar = (un)substituted phenyl; R1 = H, alkoxy, etc.; R2 = H, alkyl, etc.; R3 = SO2R12, etc.; R12 = alkyl, etc.] are prepared I are useful as inhibitors of COX-II and, therefore, may be used for the treatment of a disease treatable by administration of a selective COX-II inhibitor, such as an inflammatory disease, autoimmune disease. Processes for preparing I are claimed. 5-(2,4-Difluorophenylsulfanyl)-2-methanesulfonyl-6-methoxyquinoline in vitro showed IC50 values of >40 μM and <0.2 μM against COX-I and COX-II,

L5 ANSWER 10 OF 21 MARPAT COPYRIGHT 2005 ACS on STN (Continued)
resp. Formulations are given.

MSTR 1



G1 = CH2
G7 = Ph (SO (1-5) G28)
G8 = CN
G19 = S(O)
G20 = alkyl<(1-6)> (SR (1-3) CO2H)
MPL: claim 1
NTE: and prodrugs and pharmaceutically acceptable salts
STE: and isomers and mixtures of isomers

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 11 OF 21 MARPAT COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 133:89542 MARPAT
TITLE: Preparation of quinoxalines as non-peptide GLP-1 agonists
INVENTOR(S): Teng, Min; Truesdale, Larry Kenneth; Bhumralkar, Dilip; Kiel, Dan; Johnson, Michael D.; Thomas, Christine; Jorgensen, Anker Steen; Madsen, Peter; Olesen, Preben Houlberg; Knudsen, Liselotte Bjerre; Petterson, Ingrid Vivika; Cornelis De Jong, Johannes; Behrens, Carsten; Kodra, Janos Tibor; Lau, Jesper
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.; Agouron Pharmaceuticals, Inc.
SOURCE: PCT Int. Appl., 194 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000042026	A1	20000720	WO 2000-DK14	20000114
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1147094	A1	20011024	EP 2000-900499	20000114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002534512	T2	20021015	JP 2000-593594	20000114
PRIORITY APPLN. INFO.:			DK 1999-41	19990115
			WO 2000-DK14	20000114

GI



I

AB The title compds. I [R1, R2, R3, R4 independently = H, halogen, CN, CF3, NO2, OR5, lower alkyl, SR5, S(O2)NR5R6, etc (a proviso is given); A, B = H, halogen, OH, CF3, CF2CF3, CN, NO2, alkyl, alkenyl, etc; L, M = (CH2)mS(CH2)n, (CH2)mO(CH2)n, (CH2)mS(O)(CH2)n, (CH2)mS(O)2(CH2)n, etc; X, V = :N or :CD; D = H, halogen, CN, CF3, NO2, etc; m, n independently = 0, 1, 2, 3, or 4] useful as non-peptide GLP-1 agonists for the treatment and/or prevention of disorders and diseases wherein an activation of the human GLP-1 receptor is beneficial, especially metabolic disorders such as Type

L5 ANSWER 11 OF 21 MARPAT COPYRIGHT 2005 ACS on STN (Continued)
1 diabetes, Type 2 diabetes and obesity (no data), are prepd. Formulations are given.

MSTR 1



G1 = CN
G2 = Ph (SO)
G7 = (1-) N / 23

G11 = SO2
G14 = SO2
G15 = CF3
MPL: claim 1

REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 12 OF 21 MARPAT COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 131:58827 MARPAT
TITLE: Preparation of hypoglycemic imidazoline compounds
INVENTOR(S): Jirousek, Michael Robert; Paal, Michael; Ruhter, Gerd; Schotten, Theo; Stenzel, Wolfgang; Takeuchi, Kumiko
PATENT ASSIGNEE(S): Eli Lilly and Co., USA
SOURCE: Eur. Pat. Appl., 136 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 924209	A1	19990623	EP 1998-310461	19981218
EP 924209	B1	20030502		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CA 2315226	AA	19990701	CA 1998-2315226	19981218
WO 9932112	A1	19990701	WO 1998-US26974	19981218
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
WO 9932482	A1	19990701	WO 1998-US27080	19981218
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9920030	A1	19990712	AU 1999-20030	19981218
AU 9922016	A1	19990712	AU 1999-22016	19981218
ZA 9811672	A	20000619	ZA 1998-11672	19981218
JP 2001526286	T2	20011218	JP 2000-525419	19981218
EP 1266897	A2	20021218	EP 2002-20546	19981218
EP 1266897	A3	20031203		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO, CY, AL				
AT 239013	E	20030515	AT 1998-310461	19981218
PT 924209	T	20030829	PT 1998-310461	19981218
ES 2198033	T3	20040116	ES 1998-310461	19981218
US 6410562	B1	20020625	US 2000-581498	20001208

PRIORITY APPLN. INFO.: US 1997-68195P 19971219
EP 1998-310461 19981218
WO 1998-US26974 19981218
WO 1998-US27080 19981218

GI

L5 ANSWER 12 OF 21 MARPAT COPYRIGHT 2005 ACS on STN (Continued)



I

AB The title compds. I [X = O, S, NR5 with R5 = H, alkyl, protecting group; R1, R1', R2, R3 = H, alkyl; R1 an R2 form a bond an R1' and R3 are H, alkyl; R1 and R2 form a carbocyclic ring; R4 = heterocyclyl; n = 0-2], hypoglycemic agents, were prepared E.g., 5-chloro-2-methyl-3-(4,5-dihydro-1H-imidazol-2-yl)-1H-indole was prepared

MSTR 1C



G9 = 178

G14 = alkylene<(1-8)>
G15 = Ph (SO)
G28 = alkoxycarbonyl<(1-8)>
G30 = S(O)
G31 = alkyl<(1-10)>
MPL: claim 1
NTE: substitution is restricted

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 13 OF 21 MARPAT COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 130:38285 MARPAT
TITLE: Benzofuran derivatives useful for suppressing neurodegeneration.
INVENTOR(S): Ohkawa, Shigenori; Setoh, Masaki; Kakihana, Mitsuru; Okura, Masahiro
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 132 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9855454	A2	19981210	WO 1998-JP2482	19980604
WO 9855454	A3	19990304		
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2291026	AA	19981210	CA 1998-2291026	19980604
AU 9875503	A1	19981221	AU 1998-75503	19980604
JP 11049765	A2	19990223	JP 1998-155709	19980604
EP 988289	A2	20000329	EP 1998-923128	19980604
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRIORITY APPLN. INFO.: JP 1997-148325 19970605
WO 1998-JP2482 19980604

GI



I II

AB Title compds. I [R1, R2 = H, (un)substituted hydrocarbon group; or R1 and R2 form a 3- to 8-membered carbo- or heterocyclic ring which may be substituted; R3 = H, (un)substituted lower alkyl or aromatic group; R4 = (un)substituted aromatic or araliph. group, or acyl; X , Y = O or S which may be oxidized; benzene ring may be further substituted] and their salts are disclosed. The compds. suppress β-amyloid toxicity, and are thus useful as agents for treating of preventing neurodegenerative diseases

L5 ANSWER 13 OF 21 MARPAT COPYRIGHT 2005 ACS on STN (Continued)
such as Alzheimer's disease or Parkinsonism. Prepns. of 33 compds. I and their intermediates are described. For instance, etherification of 3-(4-isopropylphenyl)-2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-ol with 4-methoxybenzyl chloride using NaH in DMF gave 49% title compd. II. Seven example compds. gave 27.3-47.0% in vitro protection of human neuroblastoma SK-N-SH cells from β-amyloid neurotoxicity.

MSTR 2



G11—G23

G23 = Ak<EC (1-6) C, BD (0-) D (0) T> (SR (1-3) G28)
G29 = Ph (SO (1-) G30) / quinolinyl (SO (1-) G30)
G30 = alkoxycarbonyl<(1-6)> / alkylsulfonyl<(1-6)>
DER: or salts
MPL: claim 14

L5 ANSWER 14 OF 21 MARPAT COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 128:244049 MARPAT
TITLE: Preparation of 4-heteroaroylpyrazoles as herbicides
INVENTOR(S): Otten, Martina; Gotz, Norbert; Von Deyn, Wolfgang; Engel, Stefan; Kardorff, Uwe; Rack, Michael; Hill, Regina Luise; Plath, Peter; Witschel, Matthias; Westphalen, Karl-Otto; Walter, Helmut; Misslitz, Ulf
PATENT ASSIGNEE(S): BASF Aktiengesellschaft, Germany; et al.
SOURCE: PCT Int. Appl., 183 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9812192	A1	19980326	WO 1997-EP4910	19970909
W: AL, AU, BG, BR, BY, CA, CN, CZ, GE, HU, IL, JP, KR, KZ, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, UZ, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
DE 19638484	A1	19980326	DE 1996-19638484	19960920
CA 2266450	AA	19980326	CA 1997-2266450	19970909
AU 9745542	A1	19980414	AU 1997-45542	19970909
AU 736613	B2	20010802		
EP 929546	A1	19990721	EP 1997-943851	19970909
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, PT				
BR 9711404	A	19990817	BR 1997-11404	19970909
CN 1235600	A	19991117	CN 1997-199368	19970909
NZ 334549	A	20010223	NZ 1997-334549	19970909
JP 2001503030	T2	20010306	JP 1998-514251	19970909
ZA 9708451	A	19990319	ZA 1997-8451	19970919
US 6262074	B1	20010717	US 1999-254974	19990317
PRIORITY APPLN. INFO.:			DE 1996-19638484	19960920
			WO 1997-EP4910	19970909

GI


I


II

AB Title compds. [I; R = COR5; R1,R2 = H, halo, alkyl, alkoxy, etc.; R3R4 = substituted (N-oxido) CH:CHCH:N, -CH:CHN:CH, substituted CH:CHCH2NH, -CH:CHNHCH2, etc.; R5 = pyrazolyl group II; R14 = (halo)alkyl or (un)substituted Ph; R15 = H, (phenyl)alkyl, alkanoyl, alkylsulfonyl, etc.; R16 = H or (halo)alkyl] were prepared as herbicides (no data). Thus, 1-ethyl-5-hydroxypyrazole was acylated by 8-bromoquinoline-5-carboxylic acid (preparation given) to give 4-(8-bromoquinoline-5-ylcarbonyl)

L5 ANSWER 14 OF 21 MARPAT COPYRIGHT 2005 ACS on STN (Continued)
-1-ethyl-5-hydroxypyrazole.

MSTR 1

G1 = (1) 10

G3 = SO2
G4 = Ph (SO (1-) G6)
G15 = 46-2 47-4

G16 = N
G18 = S(O)
G19 = alkenyl<(2-4)>
DER: and agriculturally acceptable salts
MPL: claim 1
NTE: substitution is restricted
NTE: also incorporates claim 13, structures IIIa and IIIb
NTE: additional oxo and imino formation also claimed

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 15 OF 21 MARPAT COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 128:243961 MARPAT
TITLE: Preparation of heteroaroylcyclohexanediones as herbicides
INVENTOR(S): Otten, Martina; Gotz, Norbert; Von Deyn, Wolfgang; Engel, Stefan; Kardorff, Uwe; Plath, Peter; Hill, Regina Luise; Witschel, Matthias; Misslitz, Ulf; Westphalen, Karl-Otto; Walter, Helmut
PATENT ASSIGNEE(S): BASF Aktiengesellschaft, Germany; et al.
SOURCE: PCT Int. Appl., 86 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9812180	A1	19980326	WO 1997-EP4894	19970909
W: AL, AU, BG, BR, BY, CA, CN, CZ, GE, HU, IL, JP, KR, KZ, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, UZ, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
DE 19638486	A1	19980326	DE 1996-19638486	19960920
CA 2266526	AA	19980326	CA 1997-2266526	19970909
AU 9743833	A1	19980414	AU 1997-43833	19970909
AU 736395	B2	20010726		
EP 931070	A1	19990728	EP 1997-941998	19970909
EP 931070	B1	20030319		
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, PT, LT, LV				
BR 9711407	A	19990817	BR 1997-11407	19970909
CN 1230951	A	19991006	CN 1997-198078	19970909
NZ 334547	A	20000929	NZ 1997-334547	19970909
JP 2001501924	T2	20010213	JP 1998-514242	19970909
AT 234817	E	20030415	AT 1997-941998	19970909
ZA 9708452	A	19990319	ZA 1997-8452	19970919
US 6479436	B1	20021112	US 1999-254973	19990317
PRIORITY APPLN. INFO.:			DE 1996-19638486	19960920
			WO 1997-EP4894	19970909

GI


I


II

AB Title compds. [I; R = COR3; R1,R2 = H, halo, alkyl, alkoxy, etc.; R3 = dioxocyclohexyl group II; R4,R5,R7,R9 = H or alkyl; R6 = H, (un)substituted (cyclo)alkyl, heterocyclyl, etc.; R8 = H, alkyl, alkoxycarbonyl; R6R9 = bond or alkylene; R6R7 = O; Z = substituted (N-oxido) CH:CHCH:N, -CH:CHN:CH, substituted CH:CHCH2NH, -CH:CHNHCH2, etc.] were prepd. as herbicides (no data). Thus, 1,3-cyclohexanedione was O-acylated by 8-bromo-5-quinolinecarboxylic acid (prepn. given) and the product rearranged to give 2-(8-bromo-5-quinolyl)carbonyl-1,3-cyclohexanedione.

L5 ANSWER 15 OF 21 MARPAT COPYRIGHT 2005 ACS on STN (Continued)

MSTR 1

G1 = (1) 10

G3 = SO2
G4 = Ph (SO (1-) G6)
G15 = 46-2 47-4

G16 = N
G18 = S(O)
G19 = alkenyl<(2-4)>
DER: and agriculturally acceptable salts
MPL: claim 1
NTE: substitution is restricted
NTE: also incorporates claim 13, structures IIIa and IIIb
NTE: additional oxo and imino formation also claimed

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 16 OF 21 MARPAT COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 128:61519 MARPAT
TITLE: Preparation of novel fused pyridazine compounds as anti-allergic and anti-inflammatory agents
INVENTOR(S): Bantick, John; Hirst, Simon; Perry, Matthew
PATENT ASSIGNEE(S): Astra Pharmaceuticals Ltd., UK; Astra Aktiebolag; Bantick, John; Hirst, Simon; Perry, Matthew
SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9745428	A1	19971204	WO 1997-SE818	19970520
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2252747	AA	19971204	CA 1997-2252747	19970520
AU 9729850	A1	19980105	AU 1997-29850	19970520
AU 708849	B2	19990812		
CN 1219934	A	19990616	CN 1997-194890	19970520
BR 9709348	A	19990810	BR 1997-9348	19970520
NZ 332399	A	20000228	NZ 1997-332399	19970520
EP 1015450	A1	20000705	EP 1997-924430	19970520
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2000511174	T2	20000829	JP 1997-542159	19970520
US 5935956	A	19990810	US 1997-913060	19970905
NO 9805457	A	19981123	NO 1998-5457	19981123
KR 2000015930	A	20000315	KR 1998-709484	19981123

PRIORITY APPLN. INFO.: GB 1996-10893 19960524
WO 1997-SE818 19970520

GI

L5 ANSWER 16 OF 21 MARPAT COPYRIGHT 2005 ACS on STN (Continued)



I II

AB The title compds. [I; X = (CH2)n, CH:CH; n = 1-3; Y = CH2, C(O); R1 = H, R1R2 = a bond; R2 = H, C1-6 alkyl; Ar1 = (un)substituted thiazolyl, Ph, pyridyl, etc. (when Y = CH2, R1R2 do not together represent a bond)], in particular pyrido[h]cinnoline, pyrido[h]cinnolinone, pyridocyclopenta[1,2-c]pyridazine, pyridocyclopenta[1,2-c]pyridazinone, pyridocyclohepta[1,2-c]pyridazine and pyridocyclohepta[1,2-c]pyridazinone derivs., useful as anti-allergic and anti-inflammatory agents, were prepared Thus, reaction of Me 5,6,7,8-tetrahydro-8-oxoisoquinoline-7-acetate with 4-chlorophenylhydrazine afforded II which showed 45% inhibition of IgE production at 10 mg/kg. Certain compds. I showed activities in the chronic graft vs. host test and the inhibition of eosinophilia test with ED50's of 0.1-10 mg/kg.

MSTR 1



G6 = 39



G8 = CN / alkylsulfinyl<(1-6)> (SO (1-) F) / alkyl<(1-6)> (SR (1-) Ph)
DER: and pharmaceutically acceptable derivatives

L5 ANSWER 16 OF 21 MARPAT COPYRIGHT 2005 ACS on STN (Continued)
MPL: claim 1

L5 ANSWER 17 OF 21 MARPAT COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 127:307393 MARPAT
TITLE: Preparation of arylpyrazoloisoquinolines and cinnolinones
INVENTOR(S): Bantick, John; Bonnert, Roger; Cage, Peter; Donald, David; Furber, Mark; Hirst, Simon; Perry, Matthew; Phillips, Eifion
PATENT ASSIGNEE(S): Astra Pharmaceuticals Ltd., UK; Astra AB; Bantick, John; Bonnert, Roger; Cage, Peter; Donald, David; Furber, Mark; Hirst, Simon; Perry, Matthew; Phillips, Eifion
SOURCE: PCT Int. Appl., 77 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9734893	A1	19970925	WO 1997-SE471	19970320
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
ZA 9702150	A	19970922	ZA 1997-2150	19970312
CA 2247814	AA	19970925	CA 1997-2247814	19970320
AU 9721867	A1	19971010	AU 1997-21867	19970320
AU 712141	B2	19991028		
EP 888347	A1	19990107	EP 1997-914729	19970320
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CN 1218472	A	19990602	CN 1997-194665	19970320
BR 9708103	A	19990727	BR 1997-8103	19970320
JP 2000506884	T2	20000606	JP 1997-533412	19970320
NZ 331614	A	20000728	NZ 1997-331614	19970320
NO 9804290	A	19981027	NO 1998-4290	19980916

PRIORITY APPLN. INFO.: GB 1996-5803 19960320
GB 1996-10474 19960518
GB 1996-10894 19960524
GB 1997-862 19970116
WO 1997-SE471 19970320

GI



I

AB The title compds. I (B, D, E, G = CH, CA, or N provided that no more than one of B, D, E, and G represents CA and no more than one of B, D, E, and G

L5 ANSWER 17 OF 21 MARPAT COPYRIGHT 2005 ACS on STN (Continued)
represents N; X = CO, CS, C:NR15, CR3R6, NR4; Y = N, N+R7, CR18; Z = OR8, O; R1 = OH, alkyl; R2 = H, alkyl, cycloalkyl; R3 = H, or a bond with R2; R4 = alkyl or a bond with R2; R5 represents a bond with R1 or R8; R6 = H, alkyl, cycloalkyl, Ph, halo, etc.; R7 = alkyl, cycloalkyl; R6R7 = alkylene, X and Y forming a 5-7 member ring; R8 = H, alkyl or a bond with R5; R15, R18 = H, alkyl; Ar1 = Ph, pyridyl, pyrimidinyl, 2-benzothiazolyl, 2- or 3-quinolyl, 2-quinoxalinyl; A = halo, cyano, amino, nitro, alkyl, alkoxy) were prepd. E.g., Me 1,2-dihydro-4-hydroxy-2-methyl-1-oxo-3-isoquinolinecarboxylate, 4-chlorophenylhydrazine, and 4-toluenesulfonic acid were fused together at 150° for 10 min. to give 2-(4-chlorophenyl)-2,4-dihydro-3-hydroxy-4-methylpyrazolo[4,3-c]isoquinolin-5-one. The pharmacol. data was detd. using the chronic graft-vs.-host test and inhibition of eosinophilia.

MSTR 1A



G4 = 93

G6 = CN / Ak<(1-6)> (SR Ph (SO))
G9 = S(O)
G10 = Ak<(1-6)> (SO (1-) F)
DER: or pharmaceutically acceptable derivatives
MPL: claim 1
NTE: substitution is restricted
NTE: additional ring formation also claimed

L5 ANSWER 18 OF 21 MARPAT COPYRIGHT 2005 ACS on STN (Continued)
as retinopathy, kidney disease, nerve diseases, cataract, and arteriosclerosis, are prepd. Thus, 19 g 4-[2-(4-biphenylylsulfonyl)ethoxy]benzaldehyde and 2,4-thiazolidinedione were suspended in ethanol, treated with 2 mL piperidine, and refluxed for 16 h to give 23.6 g thiazolidinedione deriv. (II; Z = Q), which (10 g) as hydrogenated in the presence of 5% Pd-C in AcOH at 90° for 20 h to give 2.93 g [(biphenylylsulfonylethoxy)benzyl]thiazolidinedione II (Z = Q1; wherein X1 = C, Z1 = S).

MSTR 1A



G1 = CH2CH2
G4 = quinolinyl (SO (1-2) G13)
G10 = CH2
G13 = 93

DER: or pharmacologically acceptable salts
MPL: claim 1

L5 ANSWER 18 OF 21 MARPAT COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 125:195654 MARPAT
TITLE: Preparation of (azolylphenoxy)alkyl aryl or heterocyclyl sulfone derivatives having aldose reductase-inhibitory activity as hypolipidemics, hypoglycemics, and antiobesity agents
INVENTOR(S): Yanagisawa, Hiroaki; Fujita, Takeshi; Fujimoto, Koichi; Wada, Kunio; Oguchi, Minoru; Yoshioka, Takao; Fujiwara, Toshihiko; Horikoshi, Hiroyoshi
PATENT ASSIGNEE(S): Sankyo Co, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 30 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08157461	A2	19960618	JP 1994-303810	19941207

PRIORITY APPLN. INFO.: JP 1994-303810 19941207
GI



AB The title compds. (I; R1 = C1-6 alkylene; R2 = H, C1-6 alkyl, C1-4 alkoxy or alkylthio, halo, NO2, NH2, C1-4 alkylamino, di(C1-4 alkyl)amino, or C6-10 aryl, heterocyclyl, or C7-11 aralkyl each optionally having 1-3 substituents; X = C6-10 aryl or heterocyclyl optionally having 1-3 substituents; Y = O, S, NR3; wherein R3 = H, C1-6 alkyl, C1-8 acyl; Z = Q, Q1; wherein X1 = C and Z1 = O or S; or X1 = N and Z = O), which are useful for improving hyperlipidemia, hyperglycemia, obesity, impaired glucose tolerance, insulin resistance, and diabetes complications, and thereby treating or preventing impaired glucose tolerance-caused diseases such as hypertension, osteoporosis, and cachexia and diabetes complications such

L5 ANSWER 19 OF 21 MARPAT COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 122:303102 MARPAT
TITLE: Photothermographic materials.
INVENTOR(S): Kirk, Mark P.; Mott, Andrew W.
PATENT ASSIGNEE(S): Minnesota Mining and Manufacturing Co., USA
SOURCE: Eur. Pat. Appl., 14 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 631176	A1	19941228	EP 1994-304069	19940607
EP 631176	B1	20001213		
R: BE, DE, FR, GB, IT, NL				
US 5460938	A	19951024	US 1994-247651	19940523
CA 2124755	AA	19941209	CA 1994-2124755	19940531
JP 07002781	A2	19950106	JP 1994-125023	19940607
JP 2801856	B2	19980921		
US 5594143	A	19970114	US 1995-464162	19950605

PRIORITY APPLN. INFO.: GB 1993-11790 19930608
US 1994-247651 19940523
GI



AB A compound having a nucleus of the formula I are suitable for use as image stabilizers and anti-fog agents in photothermog. materials and exhibit acceptably low sensitization of human skin.

MSTR 1



G1 = alkyl<(-10)> (SO (1-) G4)
G4 = Ph
MPL: claim 2

L5 ANSWER 20 OF 21 MARPAT COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 120:54549 MARPAT
TITLE: Preparation of anellated pyrrolinones as color formers for copying paper
INVENTOR(S): Baumann, Hans; Phaff, Rox
PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.
SOURCE: Eur. Pat. Appl., 17 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 560722	A1	19930915	EP 1993-810160	19930304
EP 560722	B1	19991117		
R: BE, CH, DE, ES, FR, GB, IT, LI				
ES 2139644	T3	20000216	ES 1993-810160	19930304
US 5362872	A	19941108	US 1993-28899	19930310
JP 06240166	A2	19940830	JP 1993-52100	19930312
PRIORITY APPLN. INFO.:			CH 1992-815	19920313

GI



I



II

AB Title compds. [I; A = atoms to complete a (hetero) aromatic ring; R1-R3 = H, alkyl, alkoxy, halo, OH, etc.; R4-R6 = H, halo, cyano, alkyl, NH2, etc.; R7 = Z1NX1X2; X1X2 = H, (cyclo)alkyl, acyl, etc.; NX1X2 = heterocyclyl; Z = O, NR; R = H, (cyclo)alkyl, aryl, etc.; Z1 = (substituted) 1,4-phenylene] were prepared Thus, 4,4'-bis(dimethylamino)benzophenone-2-carboxylic acid was cyclocondensed with 2-(H2N)C6H4CO2H to give title compound II whose PhMe solution had a green-blue color. Copying paper formulations comprising I were given.

MSTR 2

L5 ANSWER 20 OF 21 MARPAT COPYRIGHT 2005 ACS on STN (Continued)



G1 = 270-21 267-22



G26 = SO2
G27 = loweralkyl
MPL: claim 11

L5 ANSWER 21 OF 21 MARPAT COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 116:174014 MARPAT
TITLE: Preparation of cyanoquinolines as herbicide safeners
INVENTOR(S): Hagen, Helmut; Pfister, Juergen; Brill, Gunter; Nilz, Gerhard; Wuerzer, Bruno; Westphalen, Karl Otto
PATENT ASSIGNEE(S): BASF A.-G., Germany
SOURCE: Ger. Offen., 28 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4014171	A1	19911107	DE 1990-4014171	19900503
EP 459140	A2	19911204	EP 1991-106568	19910424
EP 459140	A3	19920520		
EP 459140	B1	19960911		
R: BE, CH, DE, ES, FR, GB, IT, LI, NL				
ES 2091258	T3	19961101	ES 1991-106568	19910424
JP 04225960	A2	19920814	JP 1991-96845	19910426
CA 2041684	AA	19911104	CA 1991-2041684	19910502
HU 57539	A2	19911230	HU 1991-1479	19910502
HU 209438	B	19940628		
US 5565408	A	19961015	US 1995-423325	19950417
PRIORITY APPLN. INFO.:			DE 1990-4014171	19900503
			US 1991-692840	19910429
			US 1993-13232	19930203

GI



I



II



III

AB Title compds. [I; R1 - halo, OH, NO2, cyano, (un)substituted alkyl, etc.; R2 = H, halo, alkoxy, (un)substituted amino; m = 0-3] were prepared Thus, NCCH2CO2Me was cyclocondensed with isatoic anhydride to give title compound II. At 0.25 kg/ha title compound III reduced damage of an ethoximinobutylcyclohexenone herbicide (0.06 kg/ha) to rice from 90 to 15% with no effect on (complete) control of Lolium multiflorum.

MSTR 5B

L5 ANSWER 21 OF 21 MARPAT COPYRIGHT 2005 ACS on STN (Continued)



G1 = 7 / SO2Me

G4 = SO2
G5 = Ph (SO)
MPL: claim 4

09/925,883

```
=> d his

     (FILE 'HOME' ENTERED AT 12:38:46 ON 07 MAR 2005)

     FILE 'REGISTRY' ENTERED AT 12:39:22 ON 07 MAR 2005
L1              STRUCTURE UPLOADED
L2            1 S L1 SAM
L3           39 S L1 FULL

     FILE 'CA' ENTERED AT 12:39:49 ON 07 MAR 2005
L4            1 S L3

     FILE 'MARPAT' ENTERED AT 12:40:07 ON 07 MAR 2005
L5           21 S L1 FULL

=>

---Logging off of STN---


=>
Executing the logoff script...


=> LOG Y

STN INTERNATIONAL LOGOFF AT 12:40:49 ON 07 MAR 2005
```